NeuroThera Labs Inc. (TSXV: NTLX), a clinical-stage biotech company focused on central nervous system disorders, announced on August 12, 2026, that it has closed the first tranche of its non-brokered private placement, raising C$2,700,000. The company, a majority-owned subsidiary of SciSparc Ltd., sold 22,500,000 units at C$0.12 per unit, with each unit consisting of one common share and one common share purchase warrant.
The warrants entitle holders to purchase one common share at US$0.115 (approximately C$0.16) until August 12, 2029. The warrants include an acceleration provision: if NeuroThera's securities are approved for trading on the Nasdaq Stock Market, the company will accelerate the expiry date of 50% of the unexercised warrants, providing three business days' notice to holders. The warrants are non-transferable.
The company intends to use the net proceeds for general working capital, including the evaluation of prospective transactions, settlement of liabilities, and repayment of outstanding indebtedness to SciSparc Ltd., as well as other corporate and administrative expenses. All securities issued in the first tranche are subject to a four-month-and-one-day restricted period.
The offering is subject to final approval from the TSX Venture Exchange. In connection with the first tranche, the company paid C$222,750 in finder's fees to an arm's length party and issued 2,812,500 common shares as compensation to the finder.
This private placement is significant for NeuroThera as it provides essential capital to advance its operations and explore strategic opportunities. The company is at a critical stage in developing novel therapeutics for central nervous system disorders, a field with significant unmet medical needs. The funding will help the company settle liabilities and maintain financial flexibility as it pursues its development programs.
The acceleration provision linked to a potential Nasdaq listing is noteworthy. If NeuroThera's securities are approved for trading on Nasdaq, it could enhance the company's visibility and access to U.S. capital markets, potentially accelerating its growth. However, this is contingent on meeting regulatory requirements and market conditions.
The company's reliance on SciSparc, a majority shareholder, is also a key aspect. The repayment of indebtedness to SciSparc is part of the planned use of proceeds, which may reduce financial obligations to its parent company and strengthen its balance sheet.
NeuroThera's focus on central nervous system disorders positions it in a growing market, with increasing demand for innovative treatments. The successful closure of this funding round demonstrates investor confidence in the company's strategy and potential.
As with any clinical-stage biotech, there are risks, including the need for additional financing and the uncertainty of regulatory approvals. The forward-looking statements in the announcement highlight these risks, but the company remains optimistic about its future prospects.
Overall, this capital raise is a positive step for NeuroThera, enabling it to continue its mission of developing therapies for underserved conditions while maintaining operational stability.
